Search Technologies

Researchers at NCI have developed a means of more closely simulating in mouse models both melanoma cancer itself and the resulting physiological an immunological response by creating a genetically engineered mice (GEM)-derived allograft (GDA).  This allograft both resembles human-like melanoma and has features that will stimulate a normal immunological response in the mouse.

Scientists at the National Cancer Institute (NCI) isolated a panel of single domain antibodies (known as ‘nanobodies’), targeting the S2 subunit of the spike protein of SARS-CoV-2 virus. These nanobodies bind to a highly conserved region in the S2 subunit of the spike protein, suggesting the potential to treat current and future SARS-CoV infections. The NCI seeks parties interested in collaborative research and/or licensing to further develop these nanobodies as a possible treatment of COVID-19 infections.

Computer automated segmentation of high variability organs and disease features in medical images is uniquely difficult. The application of deep learning and specialized neural networks may allow for automation of such interpretation tasks that are currently only performed by trained physicians. Computer automation may improve image analysis capabilities and lead to better diagnostics, disease monitoring, and surgical planning for many diseases. To help solve this challenge, researchers at the National Institutes of Health Clinical Center (NIHCC) have developed a technology that trains a computer to read and segment certain highly variable image features, and this technology is available for licensing.

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a method to identify T cells with preferred phenotypes for increased response from adoptive immunotherapy.

Scientists at the National Cancer Institute have developed a cell line designated A549 that was derived from explanted cultures of human lung cancer tissue. The A549 cell line has been tested under the guidance of the United States Food and Drug Administration (FDA) so, under current Good Manufacturing Practices (GMP), these cells may be suitable for use in manufacturing constructs for use in clinical trials. The National Cancer Institute seeks parties to non-exclusively license this research material.

Researchers at the National Cancer Institute (NCI) have developed small molecule compounds that inhibit activity of hypoxia inducible factor 1 (HIF-1). The HIF-1 inhibitor compounds are designed around the scaffold of naturally occurring metabolite eudistidine. The invention compounds have demonstrated activity against cancer and malaria in vitro.

Researchers at the National Cancer Institute (NCI), in collaboration with researchers at the University of California, Santa Barbara (UCSB), developed a tetrahedral-shaped RNA nanoparticle for the delivery of siRNA to activate RNAi. The tetrahedral RNA nanoparticles can contain twelve Dicer substrate RNA duplexes for gene silencing. The NCI seeks parties interested in co-development or licensing of these tetrahedral RNA nanoparticles.

Researchers at the National Cancer Institute (NCI) have developed a number of analogs of the natural product englerin A, an inhibitor of renal cancer cell growth. Englerin A is thought to exert its anticancer effects by activating protein kinase C (PKC) theta, and exert cytotoxic effects through activation of transient receptor potential cation (TRPC) channels. The invention englerin analogues provide promising treatment strategies for various cancers, diabetes, and HIV, and other diseases associated with the PKC theta and/or TRPC ion channel proteins. Researchers at the NCI seek licensing and/or co-development research collaborations for englerin A analogue compounds.

The National Institute on Aging (NIA) seeks research co-development partners and/or licensees for the development of Cα-peptide as a therapeutic for the treatment of islet amyloidosis in diabetes.